What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 1
- “This is a sequential, randomized, double-blind, placebo-controlled Phase 1 single (SAD) and multiple (MAD) ascending dose study to evaluate the safety, tolerability, and pharmacokinetics (PK) of orally or intravenously administered LTG-001 in healthy male and female participants”In the company’s words, NCT06049095 on ClinicalTrials.gov
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | Sep 2026 | A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants | |
| Phase 2Completed | 8 Aug 2025 | This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars | |
| Phase 2Completed | 7 Jan 2026 | An Efficacy and Safety Study of LTG-001 Following Abdominoplasty | |
| Phase 1Completed | 17 Nov 2025 | A Study Comparing LTG-001 SDD Formulation To LTG-001 Crystalline Immediate Release Tablets In Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026